SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
November 06, 2024 17:05 ET
|
SAB Biotherapeutics, Inc.
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific Advisors
April 05, 2022 06:00 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., April 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results
March 29, 2022 16:30 ET
|
SAB Biotherapeutics, Inc.
SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised patients Plans to announce full data...
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results
March 24, 2022 06:30 ET
|
LAVA Therapeutics N.V.
LAVA-051 shows encouraging initial safety and pharmacodynamic observations; on track for more dose escalation data from Phase 1/2a trial in Q2 2022LAVA-1207 Phase 1/2a trial in mCRPC on track to...
LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022
March 10, 2022 06:30 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022
March 07, 2022 08:35 ET
|
LAVA Therapeutics N.V.
LAVA-051 preliminary data shows encouraging initial clinical safety; no dose-limiting toxicity or cytokine release syndromePharmacodynamic markers indicate increasing receptor occupancy with...
SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 Variants
March 01, 2022 19:30 ET
|
SAB Biotherapeutics, Inc.
In the FDA-conducted study, SAB-185 consistently demonstrated high avidity and high potency for effectively neutralizing a broad range of SARS-CoV-2 strains and variants through Delta SAB-185...
SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19
February 25, 2022 06:00 ET
|
SAB Biotherapeutics, Inc.
ACTIV-2 Phase 3 trial continuing as placebo-controlled study in Omicron variant COVID participants SIOUX FALLS, S.D., Feb. 25, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (SAB) (Nasdaq: SABS), a...
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer
February 01, 2022 06:30 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™...
Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022
January 28, 2022 07:00 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 28, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...